medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2006, Number 1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2006; 19 (1)

Implications of single nucleotide polymorphisms in Mycobacterium tuberculosis and humans in the clinical management of tuberculosis

Castillejos LMJ, Pérez PR, Quiñones FF, García Sancho FMC

Language: Spanish
References: 46
Page: 38-46
PDF size: 74.84 Kb.


ABSTRACT

We review studies of Mycobacterium tuberculosis genetic polymorphisms associated to resistance and transmission; also, the genetic polymorphisms associated to severity and clinical presentation of human tuberculosis (TB) and hepatic toxicity associated to antituberculosis treatment. We discuss its usefulness in studies of patients with multidrug resistant TB.
The new methods of genomic medicine suggest new criteria for immediate application in TB management, the evaluation of treatment efficacy and the prevention of patient complications. It is important to appraise cost-benefit of this tool to improve TB medical care centers from developing countries with high rates of TB.


REFERENCES

  1. Guía para la atención de pacientes con tuberculosis multifarmacorresistente. Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. México, DF., diciembre, 2004.

  2. Pérez-Padilla JR, Salazar-Lezama MA. Discrepancias entre los datos ofrecidos por la Secretaría de Salud y la Organización Mundial de la Salud sobre tuberculosis en México, 1981-1998. Salud Pública Méx 2003; 45:78-83.

  3. Laszlo A, de Kantor IN. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ 1994;72: 603-610.

  4. García-García ML, Valdespino-Gómez JL, Palacios-Martínez M, Mayar-Maya, García-Sancho C, Sepúlveda-Amor J. Tuberculosis y SIDA en México. Salud Pública Méx 1995;37:539-548.

  5. Sifuentes OJ, Ponce de León A, Camacho MFE, et al. Resistencia de Mycobacterium tuberculosis en pacientes mexicanos: características clínicas y factores de riesgo. Rev Invest Clin 1995;47:273-281.

  6. Granich RM, Balandrano S, Santaella AJ, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997. Arch Intern Med 2000;160:639-644.

  7. Peter CR, Schultz E, Moser K, et al. Drug-resistant pulmonary tuberculosis in the Baja California-San Diego County border population. West J Med 1998;169: 208-213.

  8. Olvera CR. Farmacorresistencia secundaria en tuberculosis. Tendencia en el Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp Mex 2001;14:151-159.

  9. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-430.

  10. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-183.

  11. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235.

  12. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-128.

  13. Ramaswamy SV, Reich R, Dou SJ, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:1241-1250.

  14. Cardoso RF, Cooksey RC, Morlock GP, et al. Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob Agents Chemother 2004;48: 3373-3381.

  15. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu, Natal, South Africa. Tuber Lung Dis 2000; 80:47-56.

  16. Baker LV, Brown TJ, Maxwell O, et al. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism. Antimicrob Agents Chemother 2005;49:1455-1464.

  17. Abal AT, Ahmad S, Mokaddas E. Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. Microb Drug Resist 2002;8:99-105.

  18. Herrera-Leon L, Molina T, Saiz P, Saez-Nieto JA, Jimenez MS. New multiplex PCR for rapid detection of isoniazid-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2005;49:144-147.

  19. Ahmad S, Fares E, Araj GF, Chugh TD, Mustafa AS. Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. Int J Tuberc Lung Dis 2002;6:920-926.

  20. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002;46:1417-1424.

  21. Kim SY, Park YJ, Kim WI, et al. Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis 2003;47:497-402.

  22. Hofling CC, Pavan EM, Giampaglia CM, et al. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil. Int J Tuberc Lung Dis 2005;9:87-93.

  23. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997;35:719-723.

  24. Espasa M, Gonzalez-Martin J, Alcaide F, et al. Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. J Antimicrob Chemother 2005;55:860-865.

  25. Bobadilla-del-Valle M, Ponce-de-Leon A, Arenas-Huertero C, et al. rpoB Gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism. Emerg Infect Dis 2001;7:1010-1013.

  26. Ramaswamy SV, Dou SJ, Rendon A, Yang Z, Cave MD, Graviss EA. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol 2004;53(Pt 2):107-113.

  27. Lee H, Cho SN, Bang HE, et al. Molecular analysis of rifampin-resistant Mycobacterium tuberculosis isolated from Korea by polymerase chain reaction-single strand conformation polymorphism sequence analysis. Int J Tuberc Lung Dis 1998;2:585-589.

  28. Kubica T, Agzamova R, Wright A, et al. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2005; 9:646-653.

  29. Drobniewski F, Balabanova YM, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005;293:2726-2731.

  30. Almeida D, Rodrigues C, Ashavaid TF, Lalvani A, Udwadia ZF, Mehta A. High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care centre in Bombay, India. Clin Infect Dis 2005;40:881-886.

  31. Tracevska T, Jansone I, Baumanis V, Marga O, Lillebaek T. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2003;7:1097-1103.

  32. Lan NT, Lien HT, Tung le B, Borgdorff MW, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 2003;9:1633-1635.

  33. Laserson KF, Osorio L, Sheppard JD, et al. Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998. Int J Tuberc Lung Dis 2000;4:673-683.

  34. Kubica T, Rusch-Gerdes S, Niemann S. The Beijing genotype is emerging among multidrug-resistant Mycobacterium tuberculosis strains from Germany. Int J Tuberc Lung Dis 2004;8:1107-1113.

  35. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island. Am J Respir Crit Care Med 2001;164:1165-1170.

  36. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 2003;41:1520-1524.

  37. Roth DE, Soto G, Arenas F, et al. Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis. J Infect Dis 2004;190:920-927.

  38. Zhang W, Shao L, Weng X, et al. Variants of the natural resistance-associated macrophage protein 1 gene (NRAMP1) are associated with severe forms of pulmonary tuberculosis. Clin Infect Dis 2005;40:1232-1236.

  39. Abe T, Iinuma Y, Ando M, et al. NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis. J Infect 2003;46:215-220.

  40. Henao MI, Montes C, Paris SC, Garcia LF. Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis. Tuberculosis (Edinb). 2006;86:11-19. Epub 2005.

  41. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256-261.

  42. Hiratsuka M, Kishikawa Y, Takekuma Y, et al. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002;17:357-362.

  43. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-889.

  44. Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol 2001;16:1033-1037.

  45. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37:924-930.

  46. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919.




2020     |     www.medigraphic.com